Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at the 30th Annual Cardiovascular Nursing Symposium held by the Preventive Cardiovascular Nurses Association on April 18-20th in Orlando, FL. The posters will be available following the embargo at https://MilestonePharma.com.
| Poster Presentation Title: | Characterizing Paroxysmal Supraventricular Tachycardia Episodes by
Patient-Perceived Episode Duration, Symptoms, and Severity: Longitudinal Patient-Reported Outcomes (Encore) |
| Presenter: | Richard L. Sherwood, MD |
| Date and time: | April 18, 5:30-6:30pm EST |
| Poster Presentation Title: | Assessing the Real-World Impact of Paroxysmal Supraventricular
Tachycardia on Quality of Life: A Longitudinal Study With a Focus on Anxiety Burden |
| Presenter: | Kathryn A. Wood, PhD, RN, FAHA, FAAN |
| Date and time: | April 18, 5:30-6:30pm EST |
| Poster Presentation Title: | Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of
Rapid Ventricular Rate in Patients with Atrial Fibrillation: Phase 2 ReVeRA-201 (Encore) |
| Presenter: | James Nunez, PharmD |
| Date and time: | April 18, 5:30-6:30pm EST |
